Evidence map›Paper›PMID 24016178›Full record

ArticleOmics : a journal of integrative biology2013

Functional genetic polymorphisms in CYP2C19 gene in relation to cardiac side effects and treatment dose in a methadone maintenance cohort.

Sheng-Chang Wang, Ing-Kang Ho, Hsiao-Hui Tsou, Sheng-Wen Liu, Chin-Fu Hsiao, Chia-Hui Chen, Happy Kuy-Lok Tan, Linen Lin, Chi-Shin Wu, Lien-Wen Su and 10 more

Abstract read
In one paragraph

Article in Omics : a journal of integrative biology, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 22 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
22citing papers in PubMed, 1 pooled it
4.4field-weighted citation impact, top 7% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

22 citing papers in PubMed, 1 synthesis or guideline pooled it, 35 citations in OpenAlex.

  1. Pooled it
  2. Trial
  3. Review
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Review
  10. Review
  11. Review
  12. Article
  13. GRK5 Is Associated with the Regulation of Methadone Dosage in Heroin Dependence.The international journal of neuropsychopharmacology · 2018
    Article
  14. Review
  15. Review
  16. Pharmacogenetics of Methadone Response.Molecular diagnosis & therapy · 2018
    Review
  17. Pharmacogenetic analysis of opioid dependence treatment dose and dropout rate.The American journal of drug and alcohol abuse · 2018
    Article
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

20 authors at 10 institutions in 4 countries.

Sheng-Chang Wang1 Center for Neuropsychiatric Research, National Health Research Institutes , Miaoli, Taiwan .
Ing-Kang Ho
Hsiao-Hui Tsou
Sheng-Wen Liu
Chin-Fu Hsiao
Chia-Hui Chen
Happy Kuy-Lok Tan
Linen Lin
Chi-Shin Wu
Lien-Wen Su
Chieh-Liang Huang
Yi-Hong Yang
Ming-Lun Liu
Keh-Ming Lin
Shu Chih Liu
Hsiao-Yu Wu
Hsiang-Wei Kuo
Andrew C H Chen
Yao-Sheng Chang
Yu-Li Liu
National Health Research Institutes · TWChina Medical University · CNColumbia University · USEn Chu Kong Hospital · TWFar Eastern Memorial Hospital · TWNational Taiwan University Hospital · TWNational Yang Ming Chiao Tung University · TWTaipei City Hospital · TWTaipei Municipal YangMing Hospital · TWTao Yuan General Hospital · TW

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Abstract Methadone maintenance therapy is an established treatment for heroin dependence. This study tested the influence of functional genetic polymorphisms in CYP2C19 gene encoding a CYP450 enzyme that contributes to methadone metabolism on treatment dose, plasma concentration, and side effects of methadone. Two single nucleotide polymorphisms (SNPs), rs4986893 (exon 4) and rs4244285 (exon 5), were selected and genotyped in 366 patients receiving methadone maintenance therapy in Taiwan. The steady-state plasma concentrations of both methadone and its EDDP metabolite enantiomers were measured. SNP rs4244285 allele was significantly associated with the corrected QT interval (QTc) change in the electrocardiogram (p=0.021), and the Treatment Emergent Symptom Scale (TESS) total score (p=0.021) in patients who continued using heroin, as demonstrated with a positive urine opiate test. Using the gene dose (GD) models where the CYP2C19 SNPs were clustered into poor (0 GD) versus intermediate (1 GD) and extensive (2 GD) metabolizers, we found that the extensive metabolizers required a higher dose of methadone (p=0.035), and showed a lower plasma R-methadone/methadone dose ratio (p=0.007) in urine opiate test negative patients, as well as a greater QTc change (p=0.008) and higher total scores of TESS (p=0.018) in urine opiate test positive patients, than poor metabolizers. These results in a large study sample from Taiwan suggest that the gene dose of CYP2C19 may potentially serve as an indicator for the plasma R-methadone/methadone dose ratio and cardiac side effect in patients receiving methadone maintenance therapy. Further studies of pharmacogenetic variation in methadone pharmacokinetics and pharmacodynamics are warranted in different world populations.

Indexed as

Polymorphism, Single NucleotideAdultAryl Hydrocarbon HydroxylasesCohort StudiesCytochrome P-450 CYP2C19Dose-Response Relationship, DrugFemaleGene DosageGene FrequencyGenetic Association StudiesHeart DiseasesHeroin DependenceHumansMaintenance ChemotherapyMaleMethadoneAryl Hydrocarbon HydroxylasesCYP2C19 protein, humanCytochrome P-450 CYP2C19Methadone

Identifiers

PMID24016178
PMCPMC3783925
OpenAlexW1973460885

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.